CoChat

BET Proteins as Targets for Anticancer Treatment

Stathis, Anastasios, Bertoni, Francesco · 2018 · Cancer Discovery

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

Abstract

Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression and are involved in cancer pathogenesis. Over the last years, several BET inhibitors have been developed and clinically tested. Results from the first clinical trials show limited single-agent activity in a small subset of patients with hematologic malignancies and in NUT carcinoma. Adverse events have been observed and may limit treatment compliance. Here, we review the preclinical rationale for targeting BET proteins in cancer and the preliminary results from clinical trials, and outline future directions for the use of BET inhibitors as antitumor agents. Significance: BET inhibitors represent a new class of anticancer agents. Results from the first clinical trials confirm the antitumor potential of BET inhibitors, but their efficacy as single agents seems to be limited. Based on preclinical data, combination therapies with other anticancer agents and the development of a new generation of compounds may open new possibilities for targeting BET proteins as effective anticancer strategies. Cancer Discov; 8(1); 24–36. ©2017 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-0605

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 140 references

Cited by

See all 492

Metadata

Authors
Stathis, A., & Bertoni, F.
Affiliations
  • Istituto Oncologico della Svizzera Italiana (CH)
  • Institute of Oncology Research (CH)
Venue
Cancer Discovery
Published
2018-01-01
Volume
8
Issue
1
Pages
24-36
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2779743226
Cited by
463
References
140
Citations by year
2026: 21 · 2025: 45 · 2024: 60 · 2023: 67 · 2022: 60 · 2021: 70 · 2020: 81 · 2019: 40 · 2018: 18
FWCI
3.60
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
Funders
Oncoethix and Merck for the clinical trials (OTX015/MK-8628)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
BET proteins, BET inhibitors, epigenetic reader protein, cancer epigenetics, hematologic malignancies, NUT carcinoma, combination therapy, adverse events, clinical trials, anticancer agents
MeSH terms
Carcinoma, Humans, Nuclear Proteins, Transcription Factors, Epigenesis, Genetic, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BET Proteins as Targets for Anticancer Treatment. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-0605
The paper
Stathis, A., & Bertoni, F. (2018). BET Proteins as Targets for Anticancer Treatment. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-0605

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.